- Scinai Immunotherapeutics completed the acquisition of Recipharm Israel, adding a second manufacturing site and expanding its CDMO capabilities through a strategic collaboration with Recipharm AB.
- The company reported first-quarter 2026 revenue of $489,000 and net income of $3.6 million, driven primarily by a non-cash bargain purchase gain related to the acquisition.
Scinai Immunotherapeutics Ltd. reported its financial results for the first quarter of 2026 and provided an update on the expansion of its CDMO operations following the acquisition of Recipharm Israel. The transaction added a second manufacturing and development facility in Yavne, Israel, and established a strategic commercial collaboration with Recipharm AB. The company has since consolidated its contract manufacturing activities under its wholly owned subsidiary, Scinai Biopharma Services.
According to Scinai, the acquisition broadens its development and manufacturing capabilities by combining its biologics-focused facility in Jerusalem with the newly acquired Yavne site. The integrated platform now offers services spanning biologics, sterile injectable products, and small-molecule API development and manufacturing. The company said the collaboration with Recipharm AB is intended to provide customers with development and manufacturing solutions ranging from early-stage development to commercial-scale production.
For the three months ended March 31, 2026, Scinai reported revenue of $489,000 compared with $586,000 in the prior-year period. Revenue included approximately $200,000 generated by the Yavne facility following completion of the acquisition. Net income was $3.6 million, compared with a net loss of $1.6 million in the first quarter of 2025, primarily due to a non-cash bargain purchase gain of $6.2 million associated with the Recipharm Israel transaction.
“The first quarter of 2026 marked an important milestone in Scinai’s evolution. Through the acquisition of Recipharm Israel and the subsequent consolidation of our CDMO activities under Scinai Biopharma Services, we have expanded our operational footprint, manufacturing capabilities and commercial reach.”
Amir Reichman, Chief Executive Officer of Scinai
Scinai stated that the acquisition added approximately $6.2 million in net identifiable assets to its balance sheet, including cash, manufacturing infrastructure, and equipment. The company believes the combined Jerusalem and Yavne operations will provide greater revenue diversification, expanded customer opportunities, and a broader contract manufacturing service offering while supporting the advancement of its immunology-focused research and development programs.
